A little review for newbies>>>>>>>>>>>>>"The science behind NEUPREX®, and the BPI platform for product development, are complementary to our recombinant and vaccines businesses," said Thomas Glanzmann, president, Hyland Immuno. "It serves as an excellent illustration of the strategic growth underway at Hyland Immuno as we diversify our biotechnology portfolio."
"We're pleased to have Baxter as our ally," said Jack Castello, chairman, president and CEO of XOMA. "They have excellent worldwide marketing and sales capabilities, particularly in the critical care and emergency hospital market. With Baxter's involvement, we believe we can maximize the value of NEUPREX® by aiming not only for meningococcemia but also for a wide variety of other medical indications."
"I am delighted about this relationship with XOMA," said Norbert Riedel, Ph.D., president of Hyland Immuno's Recombinant business. "NEUPREX® addresses an unmet medical need for a critically-ill patient population, and allows Baxter Hyland Immuno the opportunity to bring this product as quickly as possible to the patient and their families who so desperately need it."<<<<<<<<<<<<<<<<<<<<<<<<< |
